Common

Return to Sender? Only If It’s Convenient

Retrieved on: 
Tuesday, April 2, 2024
Software, Other Retail, Technology, Supply Chain Management, Fashion, Retail, Security, Department Stores, SCA, Common, Financial services, Ageing, Research, Marketing, PayPal, Collection, OnePoll, Online shopping

This underscores the importance of going beyond the "buy now" button and focusing on the entire retail life cycle, from delivery to return.

Key Points: 
  • This underscores the importance of going beyond the "buy now" button and focusing on the entire retail life cycle, from delivery to return.
  • Return policies drive buying decisions: 86% of Spanish consumers consider return policies very or fairly important when choosing a retailer, with well over half of those saying “very important.” Overall, 77% of European consumers agreed that return policies are fairly or very important.
  • Ease of return is paramount: 83% of respondents across Europe find ease of return crucial, reflecting sentiment in Spain where 91% agreed that easy returns were vital.
  • Preferred return methods vary: Spanish consumers agreed with other Europeans that courier collection provided their preferred return experience (39%).

Fonon Highlights BlackStar Wafer Dicing Machine for Semiconductor Industry Applications

Retrieved on: 
Friday, March 29, 2024
Semiconductor, Security, Manufacturing, Audio, Video, Other Science, Other Technology, Networks, Hardware, Electronic Design Automation, Science, Consumer Electronics, Technology, Mobile, Wireless, Robotics, Other Manufacturing, Steel, Engineering, Machine Tools, Metalworking & Metallurgy, Chemicals, Plastics, Fantom, Germanium, Blackstar (TV series), Common, Corporation, Silicon, Water, Fracture

Fonon Corporation , a multi-market holding company, R&D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights its BlackStar Wafer Dicing Machine for applications in the semiconductor industry.

Key Points: 
  • Fonon Corporation , a multi-market holding company, R&D center, equipment designer and manufacturer of advanced laser material processing systems for subtractive and additive manufacturing, highlights its BlackStar Wafer Dicing Machine for applications in the semiconductor industry.
  • The manufacturing of semiconductor chips involves cutting, or singulating, small-scale dies out of silicon wafers.
  • Fonon’s FWLD technology allows for the production of multiple size dies on the same wafer and the dicing of complex shapes.
  • The BlackStar can dice a wide variety of semiconductor materials, including silicon, gallium arsenide, germanium, indium phosphide, silicon carbide, gallium nitride, gallium phosphide and other compound materials.

Empire Petroleum Announces Modification of Terms of Previously Announced Rights Offering

Retrieved on: 
Thursday, March 28, 2024
Oil, Gas, Energy, Transfer, Common stock, Letter, The Company, Exercise, Common, Sale, News, Expiration, Security (finance), Prospectus, Rights, Eastern Time Zone

Empire Petroleum Corporation (NYSE American: EP) ("Empire" or the "Company"), an oil and gas company with current producing assets in New Mexico, North Dakota, Montana, Texas, and Louisiana, announced today that it has modified the terms of its previously announced subscription rights offering (“Rights Offering”).

Key Points: 
  • Empire Petroleum Corporation (NYSE American: EP) ("Empire" or the "Company"), an oil and gas company with current producing assets in New Mexico, North Dakota, Montana, Texas, and Louisiana, announced today that it has modified the terms of its previously announced subscription rights offering (“Rights Offering”).
  • In addition, holders of subscription rights who fully exercise their subscription rights are entitled to over-subscribe for additional shares of Common Stock, subject to proration.
  • Holders of subscription rights who hold their shares directly have received a prospectus, a prospectus supplement, a letter from Empire describing the Rights Offering, and a subscription rights certificate.
  • Those holders who intend to exercise their subscription rights and over-subscription rights should review all of these materials, properly complete and execute the subscription rights certificates, and deliver the subscription rights certificates and full payment to Securities Transfer Corporation, the subscription agent for the Rights Offering, at the address set forth in the prospectus supplement referenced below.

Franklin Covey Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Other Professional Services, Human Resources, Consulting, Other Education, Continuing, Professional Services, Education, Training, Organization, FC, Consolidated, Growth, Finance, Impaired asset, Environment, Tax, International, Telephone, Common, Perception, History, Sale, All Access Pass, Adjustment, Behavior, Depreciation, Walker, Income tax, AAP, Herd, Collection, Marketing, Person, Video game

Net income for the second quarter was $0.9 million, or $0.06 per diluted share, compared with $1.7 million, or $0.12 per diluted share, in the second quarter of fiscal 2023.

Key Points: 
  • Net income for the second quarter was $0.9 million, or $0.06 per diluted share, compared with $1.7 million, or $0.12 per diluted share, in the second quarter of fiscal 2023.
  • Adjusted EBITDA for the second quarter of fiscal 2024 was slightly better than expected at $7.4 million compared with $8.2 million in fiscal 2023.
  • Operating Income: As a result of the factors noted above, the Company’s income from operations for the second quarter of fiscal 2024 was $1.4 million, compared with $2.8 million in the second quarter of fiscal 2023.
  • On Wednesday, March 27, 2024, at 5:00 p.m. Eastern (3:00 p.m. Mountain) Franklin Covey will host a conference call to review its fiscal 2024 second quarter financial results.

Introducing ArmorCode Risk Prioritization, the Most Intelligent Risk Scoring Algorithm in ASPM

Retrieved on: 
Tuesday, March 26, 2024
Software, Technology, Security, Apps, Applications, Organization, Common, SLA, ASPM, Ecosystem, Risk management

ArmorCode, the leading unified Application Security Posture Management (ASPM) platform for managing vulnerabilities and weaknesses across applications, infrastructure, and the software supply chain, today announced ArmorCode Risk Prioritization, providing the industry’s first 3D scoring approach for managing application security risks.

Key Points: 
  • ArmorCode, the leading unified Application Security Posture Management (ASPM) platform for managing vulnerabilities and weaknesses across applications, infrastructure, and the software supply chain, today announced ArmorCode Risk Prioritization, providing the industry’s first 3D scoring approach for managing application security risks.
  • “We’re proud to lead this new approach to risk reduction,” said Mark Lambert, Chief Product Officer for ArmorCode.
  • “With ArmorCode Risk Prioritization, organizations are taking a major step forward to significantly improve their security and developer team experience by fixing the highest-risk findings first.
  • ArmorCode can also trigger automated remediation workflows based on risk scores to increase security team productivity.

Politan Nominates Two Independent Candidates for Masimo Board

Retrieved on: 
Monday, March 25, 2024
Banking, Professional Services, Finance, Analytical chemistry, Biophysical environment, Health, Lead, Doctor of Philosophy, IP, M&A, Audit committee, Corporate spin-off, Audit, WHEN, WILL, Science, MASI, Stryker Corporation, Laboratory, Dentsply Sirona, Compensated emancipation, Common stock, Financial management, Knowledge, Broadcom Inc., Acquisition, Security (finance), Senior, INC, Avient Corporation, Annual general meeting, Separation, WALL, MIT, Common, Hope College, Stanford University, National academy, Government, COGS, Management

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Key Points: 
  • Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
  • Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated:
    “When shareholders overwhelmingly elected Michelle Brennan and me to the Masimo Board last year, we were optimistic we could work productively with the rest of the Board to drive positive change.
  • However, at this stage the Board has been provided zero details, and Politan has serious concerns given the lack of basic governance and oversight we have observed since joining the Board.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito, William Jellison and Darlene Solomon (collectively, the “Participants”).

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024
FDA, Health, Other Health, Pharmaceutical, Cardiology, Biotechnology, Photograph, Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Webcast, Committee, Spasm, Splenic infarction, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, U.S. FDA, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Rupture, Molina Healthcare, Hypersensitivity, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Multimedia, Uric acid, Dietary supplement

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • View the full release here: https://www.businesswire.com/news/home/20240322544788/en/
    U.S. FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Ault Alliance Announces a Final Distribution of TOG Securities Valued at Approximately $0.019 for Each Share of Ault Alliance Common Stock

Retrieved on: 
Friday, March 22, 2024
Technology, Finance, Professional Services, Digital Cash Management, Digital Assets, Blockchain, Hardware, Cryptocurrency, Data Management, Artificial Intelligence, Date, Common, Sale, Security (finance), Distribution, Prospectus, OTC, COB

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company, (“Ault Alliance” or the “Company”), hereby announces an update on its final distribution (the “Final Distribution”) related to securities of TurnOnGreen, Inc., formerly Imperalis Holding Corp. (OTC: IMHC) (“TurnOnGreen”).

Key Points: 
  • Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company, (“Ault Alliance” or the “Company”), hereby announces an update on its final distribution (the “Final Distribution”) related to securities of TurnOnGreen, Inc., formerly Imperalis Holding Corp. (OTC: IMHC) (“TurnOnGreen”).
  • In the initial distribution, Ault Alliance stockholders received forty (40) shares of TurnOnGreen common stock and warrants to purchase forty (40) shares of TurnOnGreen common stock (the “TOG Securities”) and in the second distribution, stockholders of the Company received fifteen (15) TOG Securities for each share of common stock of the Company that they owned on the record date.
  • The Company distributed 58,686,480 TOG Securities in the initial distribution and another 56,405,175 TOG Securities in the second distribution, for an aggregate of 115,091,655 TOG Securities distributed, leaving another 24,908,345 TOG Securities to be distributed in the Final Distribution.
  • Based on the estimated number of shares of common stock of the Company (the “AAI Common Stock”) to be issued and outstanding on the Record Date, each stockholder of the Company will receive approximately 0.71 TOG Securities for each share of AAI Common Stock owned on the Record Date.

Global Coffee Market Size and Forecast Report, 2023-2024 and 2030: Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Retail, Agriculture, Natural Resources, Food, Beverage, Online, Element, Espresso, Consumer, Quality control, Culture, Farmer, Taste, Convenience, Urbanization, Country, Exchange, Nutrient, Coffee, International Coffee Organization, Common, Policy, Seed, Mineral, ICO, Drink, Caffeine, Artificial intelligence, Spice, Instant coffee

The "Global Coffee Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coffee Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • As per the International Coffee Organization (ICO), global coffee consumption in 2023 reached 175.6 million 60-kg bags, equivalent to approximately 2.25 billion cups daily.
  • Latin America is anticipated to lead the global coffee market mainly owing to the presence of the biggest coffee producer, that is, Brazil.
  • By product type, the global coffee market is fragmented into Instant Coffee, Ground Coffee, Whole Grain, and Others.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
Monday, March 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.